"Analysts estimate the 2011 Russian pharmaceutical market to stand at an impressive 670 billion roubles (US$21.6 billion). At the same time, imported medications accounted for 76 per cent of total sales" - Dmitrii Medvedev, Russian Prime Minister, 18 September 2012
"(The Russian) pharmaceutical market soared from a 2005 valuation of US$6.6. billion to almost three times that in 2010, when it was worth approximately US$18.7 billion, climbing at a remarkable Compound Annual Growth Rate (CAGR) of 23 per cent..............GlobalData expects this growth to continue at a less staggering, yet still impressive CAGR of 9.5 per cent to reach US$46.4 billion by the end of 2020" - GlobalData, 25 June 2012
"Russia is committed to building its biotech industry by forming partnerships with the leading world players. We aim to boost domestic production of generics and innovative pharmaceuticals through a major programme of co-licensing and investment in first-class infrastructure and education programmes. Cooperation with international leaders in drug discovery and development is essential if we are to transform the Russian biotech industry" - Denis Manturov, Russian Minister of Industry & Trade, 18 June 2012
"The government will......channel over 120 billion roubles (U.S.$4.3 billion) to modernise the national pharmaceutical and medical equipment industries and to build up technology reserves, under a new federal programme until 2020. The plan is to establish 17 research centres to develop new drugs and design medical equipment. In 2010 alone, Russian and foreign companies invested over 40 billion roubles (U.S.$1.4 billion) to develop the production of pharmaceuticals and medical equipment" - Prime Minister Vladimir Putin, Address to State Duma, 20 April 2011
Biopharm Analytica offers a range of bespoke consulting and research services with regard to the bioscience and pharmaceutical sectors in Russia and the Newly Independent States. The UK-based company has undertaken market surveys for leading biotechnology multinationals and completed studies of niche technologies and markets. To discuss your detailed requirements with one of our analysts please call +44 (0)121 2702854 .
Biopharm Analytica also provides access to an independent English language online business news and information service focusing on developments in biotechnology and the pharmaceutical industry in Russia and the Newly Independent States (NIS). One of its key focuses is on the identification of potential opportunities for international companies with a strong emphasis on high-value projects. Coverage is also provided of ongoing pharmaceutical and biotech R&D and manufacturing within the region. Annual subscription to Biopharm Analytica by registered users, will allow immediate and privileged access to the information service covering major news stories impacting upon the biotechnology and pharmaceutical sectors in Russia and the NIS. A major searchable on-line database of news reports covering the period 2004-2012, providing an invaluable source of business intelligence with regard to the Russian biopharmaceutical sector, is available only to subscribers. It is anticipated that Biopharm Analytica's news service will rapidly become an indispensable adjunct to those companies and analysts seeking real-time news and information focused on the Russian and NIS biotechnology and pharmaceutical sectors. To discuss your subscription requirements with one of our sales staff please call +44 (0)121 2702854 or email firstname.lastname@example.org.
© Biopharm Analytica Limited 2013. All Rights Reserved. This site is owned and operated by Biopharm Analytica Limited. Registered Office: Suite B, 29 Harley Street, London, W1G 9QR. Registered in England and Wales. Reg. No. 5360763. VAT Reg. No. 930 3219 57.